Rejuvenation Technologies

The company's primary business is the development of therapies that prevent and treat chronic age-related diseases. Its core technology involves using modified mRNA to transiently activate telomerase, the enzyme responsible for extending telomeres, which are the protective caps at the ends of chromosomes that shorten with cell division. This shortening is considered a fundamental cause of aging-related diseases. The company's lead product is a telomerase mRNA therapeutic encapsulated in proprietary, tissue-targeted lipid nanoparticles (LNPs) for delivery to specific organs like the liver and lungs. A key feature of this approach is its temporary nature, which allows for precise control over telomere extension, a critical safety factor that prevents the immortalization of cells. A single dose has been shown in preclinical models to reverse years of telomere shortening within hours.

Rejuvenation Technologies operates in the longevity and regenerative medicine market, targeting fatal diseases with high unmet medical needs. Their initial clinical focus is on fibrotic diseases such as pulmonary fibrosis and liver cirrhosis. The business model is centered on advancing these therapeutic programs through clinical trials to eventually gain regulatory approval. The company has secured significant funding, including a $10.6 million seed round led by Khosla Ventures in September 2023, which brought its total raised capital to $15.2 million, including grants. This capital is being used to advance its programs toward Investigational New Drug (IND) approval, scale up manufacturing, and expand its research and development efforts.